Research programme: estrogen-related receptor alpha modulators - Galapagos

Drug Profile

Research programme: estrogen-related receptor alpha modulators - Galapagos

Alternative Names: ERR1 - Galapagos

Latest Information Update: 28 Oct 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProStrakan
  • Class
  • Mechanism of Action ERRalpha estrogen-related receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 28 Oct 2010 Discontinued - Preclinical for Osteoporosis in France (unspecified route)
  • 22 Dec 2006 Galapagos NV acquires ProStrakan's drug discovery unit
  • 27 May 2005 Preclinical trials in Osteoporosis in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top